B+
Overall grade
B
Financial quality
The sleeper story is Shield's economics converging on Cologuard's profitability while maintaining superior adherence, potentially creating an unassailable competitive moat in blood-based screening. The obvious revenue beat and strong 2026 guidance mask a more concerning deceleration in G360 volume growth from 40% to 38% and management's regression from 'more than 30%' to 'nearly 30%' language. The binding constraint isn't demand but execution - Shield's commercial payer contracting speed will determine ASP sustainability, while G360's plateau risk emerges despite Smart apps supposedly driving adoption. Most revealing quote: 'We are not counting any kind of contribution from Quest co-promotion' - a notable walk-back from Q3's bullish positioning. My view changes if G360 liquid growth drops below 25% or Shield ASP falls below $750, signaling either market saturation or reimbursement challenges.
The 30-second version
- Shield is quietly converging on Cologuard's economics while Exact Sciences burns cash on expansion
- Oncology hit cash flow positive one quarter early, but the real story is 4.5 tests per patient per lifetime
- They stopped breaking out G360 liquid vs tissue volume growth for the first time
What changed this quarter
| Metric | Prior | This quarter |
|---|---|---|
| Total Revenue | $265.2M (+39% YoY) | $281.3M (+39% YoY) |
| Oncology Revenue | $184.4M (+31% YoY) | $189.9M (+30% YoY) |
| Oncology Test Volumes | ~74K (+40% YoY) | ~79K (+38% YoY) |
| Shield Revenue | $24.1M (~24K tests) | $35.1M (~38K tests) |
| Shield ASP | ~$880 | ~$850 |
| Shield Gross Margin | 55% | 52% |
| Shield Cost Per Test | Under $500 | ~$450 |
| Non-GAAP Gross Margin | 66% | 66% |
Accountability tracked
8 new promises made4 narrative shifts flagged7 prior promises graded
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Subscribe to Call Sheet Daily →